866-997-4948(US-Canada Toll Free)

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 48 Pages

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2017, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline landscape.

Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview 6
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development 20
Antibiotx ApS 20
ContraFect Corp 20
Debiopharm International SA 20
Destiny Pharma Ltd 21
Sealife PHARMA GMBH 21
Tetraphase Pharmaceuticals Inc 22
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles 23
afabicin - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
CF-301 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
exeporfinium chloride - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
NAI-108 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
niclosamide - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
SLP-0904 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
SLP-0905 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules for Bacterial Infections - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
targocil - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
TP-271 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects 44
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products 45
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones 46
Featured News & Press Releases 46
Dec 02, 2014: ContraFect Submits Complete Response to IND Clinical Hold for CF-301 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Products under Development by Companies, H2 2017 10
Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Stage and Target, H2 2017 13
Number of Products by Stage and Mechanism of Action, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Antibiotx ApS, H2 2017 20
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by ContraFect Corp, H2 2017 20
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, H2 2017 21
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Ltd, H2 2017 21
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2017 22
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 22
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H2 2017 44
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H2 2017 45

List of Figures
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Number of Products by Targets, H2 2017 12
Number of Products by Stage and Targets, H2 2017 12
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *